TABLE 1.
Distribution of capsular serotype determined by serotyping method among 195 clinical isolates by clinical diseasea
| Clinical disease | No. (%) of isolates
|
P | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MSSA
|
MRSA
|
Total
|
|||||||||||
| No. | Type 5 | Type 8 | NT | No. | Type 5 | Type 8 | NT | No. | Type 5 | Type 8 | NT | ||
| Suppurative infections | 113 | 36 (32) | 64 (57) | 13 (11) | 59 | 37 (63) | 10 (17) | 12 (20) | 172 | 73 (42.5) | 74 (43) | 25 (14.5) | NS |
| Skin and soft tissues | 12 | 4 | 6 | 2 | 13 | 9 | 3 | 1 | 25 | 13 | 9 | 3 | NS |
| Muskuloskeletal | 12 | 7 | 4 | 1 | 8 | 4 | 1 | 3 | 20 | 11 | 5 | 4 | NS |
| Genitourinary tract infection | 2 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 3 | 1 | 1 | 1 | NS |
| Non-necrotizing pneumonia | 7 | 1 | 6 | 0 | 7 | 5 | 0 | 2 | 14 | 6 | 6 | 2 | NS |
| Necrotizing pneumonia | 46 | 8 | 34 | 4 | 6 | 1 | 4 | 1 | 52 | 9 | 38 | 5 | <0.001 |
| Infected endocarditis | 3 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 3 | 1 | 1 | 1 | NS |
| Multifocal infection | 3 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 3 | 2 | 1 | 0 | NS |
| Bacteremia | 28 | 12 | 11 | 5 | 24 | 18 | 2 | 4 | 52 | 30 | 13 | 9 | 0.003 |
| Toxin-associated infections | 11 | 0 (0) | 11 (100) | 0 | 8 | 6 (75) | 1 (12.5) | 1 (12.5) | 19 | 6 (32) | 12 (63) | 1 (5) | NS |
| Bullous impetigo | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | NS |
| Toxic shock syndrome | 5 | 0 | 5 | 0 | 1 | 0 | 1 | 0 | 6 | 0 | 6 | 0 | 0.023 |
| Scarlet fever | 5 | 0 | 5 | 0 | 2 | 1 | 0 | 1 | 7 | 1 | 5 | 1 | NS |
| NTED | 0 | 0 | 0 | 0 | 5 | 5 | 0 | 0 | 5 | 5 | 0 | 0 | 0.027 |
| Colonization | 2 | 1 (50) | 1 (50) | 0 (0) | 2 | 1 (50) | 1 (50) | 0 (0) | 4 | 2 (50) | 2 (50) | 0 (0) | NS |
| Total | 126 | 37 (29.3) | 76 (60.3) | 13 (10.3) | 69 | 44 (64) | 12 (17) | 13 (19) | 195 | 81 (42) | 88 (45) | 26 (13) | |
a
NT, nontypeable by serotyping with capsular type 5 and 8 antibodies; non-type 5 and non-type 8. NS, not significant.